Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
14 studies found for:    SAR236553 | Sanofi [Lead] | Regeneron | Phase 3
Show Display Options
Rank Status Study
1 Completed
Has Results
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
Condition: Hypercholesterolemia
Interventions: Drug: Alirocumab;   Drug: Ezetimibe;   Drug: Placebo (for Alirocumab);   Drug: Placebo (for Ezetimibe)
2 Completed
Has Results
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)
Condition: Hypercholesterolaemia
Interventions: Drug: Alirocumab;   Drug: Placebo (for alirocumab);   Drug: Lipid Modifying Therapy (LMT)
3 Completed
Has Results
Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
Condition: Hypercholesterolemia
Interventions: Drug: Placebo (for alirocumab);   Drug: Alirocumab;   Drug: Lipid-Modifying Therapy (LMT)
4 Completed
Has Results
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
Condition: Hypercholesterolemia
Interventions: Drug: Placebo (for alirocumab);   Drug: Alirocumab;   Drug: Lipid-Modifying Therapy (LMT)
5 Completed
Has Results
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Condition: Hypercholesterolemia
Interventions: Drug: Alirocumab;   Drug: Placebo (for alirocumab);   Drug: Lipid Modifying Therapy (LMT)
6 Completed
Has Results
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)
Condition: Hypercholesterolemia
Interventions: Drug: Alirocumab;   Drug: Placebo (for alirocumab);   Drug: Ezetimibe;   Drug: Placebo (for ezetimibe);   Drug: Lipid Modifying Therapy (LMT)
7 Recruiting Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Drug: placebo for alirocumab;   Drug: ezetimibe;   Drug: placebo for ezetimibe;   Drug: atorvastatin;   Drug: rosuvastatin;   Drug: simvastatin
8 Recruiting ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
Condition: Acute Coronary Syndrome
Interventions: Drug: alirocumab;   Drug: Placebo
9 Active, not recruiting Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Condition: Hypercholesterolaemia
Interventions: Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo;   Drug: insulin;   Drug: statin;   Drug: lipid modifying therapy
10 Recruiting Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin
Condition: Hypercholesterolaemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Drug: placebo;   Drug: atorvastatin;   Drug: fenofibrate;   Drug: bezafibrate;   Drug: ezetimibe
11 Recruiting Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
Condition: Hypercholesterolemia
Interventions: Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo (for injection training only)
12 Active, not recruiting Open Label Study of Long Term Safety Evaluation of Alirocumab
Condition: Hypercholesterolemia
Intervention: Drug: Alirocumab SAR236553 (REGN727)
13 Completed
Has Results
Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)
Condition: Hypercholesterolemia
Interventions: Drug: Placebo (for alirocumab);   Drug: Alirocumab;   Drug: Lipid-Modifying Therapy (LMT)
14 Active, not recruiting Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)
Condition: Hypercholesterolemia
Interventions: Drug: Alirocumab;   Drug: Placebo (for alirocumab);   Drug: Non-statin Lipid Modifying Therapy (LMT)

Indicates status has not been verified in more than two years